Mr Claudio Carini | Global Head Clinical Immunology and Biomarkers
Pfizer

Leads biomedical research in the area of inflammation and personalized medicine. Studied Medicine in Italy and trained in internal medicine and clinical immunology. Completed PhD in Immunology at the University College London (UCL), London. Completed membership of the Royal College of Pathologists, London and Specialist Diplomas in Clinical Immunology and Respiratory Medicine, School of Medicine, Rome.
Presently is the Global Head Clinical Immunology and Biomarkers at Pfizer and a Hon. Faculty at King’s College, School of Medicine, London.  Held faculty positions at Harvard, Johns Hopkins, UCL, Rome and senior roles at Wyeth, Novartis, and Roche.
 
Presently serving in national and international scientific boards:
F-NIH Biomarkers Consortium “Inflammation & Immunology” Steering Committee
F-NIH Biomarkers Consortium “RA Working Group” Steering Committee
F-NIH Biomarkers Consortium “SLE Working Group” Steering Committee
F-NIH Biomarkers Consortium “Ankylosing Spond.Working Group” Steering Committee
MRC, (UK “Inflammation/ Immunology Initiative - UK RA Consortium, Steering Committee
MRC, (UK) “Stratified Medicine, SLE Consortium, Steering Committee
Biomarkers Development Center, Amsterdam, NL, Advisory Board
IMI, ABIRISK, European Union/EFPIA” Board of Directors
The PML Consortium, Board of Directors
 
Research interests include understanding the role of biomarkers and precision medicine in autoimmune diseases
 
Published widely in areas of immunology and molecular medicine. Over 200 publications in national and international peer reviewed journals.
 
Chaired a conference on “Companion Diagnostics: From Biomarkers Identification to Market Entry” New York Academy of Science, 2014
Co-edited two books in the field of Personalized Medicine:
“Biomarkers in Drug Development: A handbook of practice, application and strategy”, John Wiley, 2010
“Clinical and Statistical Considerations in Personalized Medicine”, CRC, 2014
 
Member of various national and international societies.